No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy results from a randomized clinical trial of 303 patients

Cancer

Volumn 71, Issue 5, 1993, Pages 1741-1745

  Lebeau, B ^a,g   Chastang, C ^b   Muir, J F ^c   Vincent, J ^d   Massin, F ^e   Fabre, C ^f  

^a HÔPITAL SAINT ANTOINE   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c Hǒpital de la Rochelle ^*  (France)

^d Hǒpital de la Trouhaude ^*  (France)

^e Service de Pneumologie   (France)

^f Centre Hospitalier Intercommunal Le Raincy Montfermeil   (France)

^g SORBONNE UNIVERSITÉ   (France)

Author keywords

aspirin; blood coagulation; chemotherapy; prognostic factors; randomized clinical trial; small cell lung cancer

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; LOMUSTINE;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS INHIBITION; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTE AGGREGATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPIRIN; CARCINOMA, SMALL CELL; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMAN; LOMUSTINE; LUNG NEOPLASMS; MALE; MELPHALAN; MIDDLE AGE; PLATELET AGGREGATION; PREDNISONE; SURVIVAL RATE;

EID: 0027403212     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19930301)71:5<1741::AID-CNCR2820710507>3.0.CO;2-Q     Document Type: Article

References (22)

1. Malignancy and haemostasis
2. Antimetastatic effects associated with platelet reduction
3. Antimetastatic effect of aspirin
4. Antimetastatic effect of aspirin
5. Potential role of platelets in the pathogenesis of tumor metastasis
6. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck and prostate: final report of VA Cooperative Study 75
7. Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non‐cross‐resistant combinations
8. Six vs twelve cycles for complete responders to chemotherapy in small cell lung cancer: de finitive results of a randomized clinical trial
9. A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction
10. Planning the size and duration of a clinical trial studying the time to some critical event
11. Non parametric estimation from incomplete observations
12. Design and analysis of randomised clinical trials requiring prolonged observations of each patient: II. Analysis and examples
13. State of the art: small cell lung cancer
14. Anticoagulants in the treatment of small cell carcinoma of the bronchus
15. Heparin and chemotherapy in the management of inoperable lung carcinoma
16. Heparin and polychemotherapy for treatment of lung cancer
17. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small cell lung cancer by the Cancer and Leukemia Group B
18. Platelets acquire a secretion defect after high‐dose chemotherapy
19. Sequential changes in platelet function and coagulation in leukemic children treated with L‐asparaginase, prednisone and vincristine
20. Initial clinical and paraclinical data of the 304 small cell broncho‐pulmonary carcinomas of 01PC83 trial
21. Abnormal regulation of coagulation‐fibrinolysis in small cell carcinoma of the lung
22. Subcutaneous heparin treatment increases complete response rate and overall survival in small cell lung cancer